CD274 and neoplasm: Based on PD-L1/TIL status, NSCLC tumor immune microenvironments were divided into type I (PD-L1+, TIL+), type II (PD-L1−, TIL−), type III (PD-L1+, TIL−) and type IV (PD-L1−, TIL+) [76].